Shanghai New Stone Biopharmaceutical

New Stone Biopharmaceutical is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative therapies for autoimmune and inflammatory diseases. The company focuses on high-value targets within the IL-17 and IL-23 pathways, aiming to provide more effective and safer treatment options for conditions such as psoriasis and ankylosing spondylitis. Their lead candidate, NS01, is a monoclonal antibody targeting IL-17A that has demonstrated promising efficacy and safety profiles in clinical trials. By leveraging a deep understanding of immunology, New Stone Biopharmaceutical is building a robust pipeline of biologics and small molecules to address significant unmet medical needs in the chronic inflammation space.